Terns Pharmaceuticals Stock Analysis

Terns Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.3. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Terns Pharmaceuticals recorded a loss per share of 1.27. The entity had not issued any dividends in recent years. The firm had 1000:50 split on the 4th of November 2013. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Terns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. To find out more about Terns Pharmaceuticals contact Senthil Sundaram at 650 525 5535 or learn more at https://www.ternspharma.com.

Terns Pharmaceuticals Investment Alerts

Terns Pharmaceuticals Upcoming and Recent Events

Terns Largest EPS Surprises

View All Earnings Estimates

Terns Pharmaceuticals Thematic Classifications

Terns Stock Institutional Investors

Note, although Terns Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Terns Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 303.22 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Terns Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Terns Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Terns Profitablity

Management Efficiency

Terns Pharmaceuticals has return on total asset (ROA) of (0.2308) % which means that it has lost $0.2308 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3389) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals' management efficiency ratios could be used to measure how well Terns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to drop to -0.35. In addition to that, Return On Capital Employed is likely to drop to -0.42. At this time, Terns Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 25th of April 2024, Non Current Assets Total is likely to grow to about 1.4 M, while Total Assets are likely to drop about 170.3 M.

Technical Drivers

As of the 25th of April, Terns Pharmaceuticals has the Semi Deviation of 5.22, coefficient of variation of 5650.59, and Risk Adjusted Performance of 0.0199. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Terns Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Terns Pharmaceuticals, which can be compared to its competition. Please validate Terns Pharmaceuticals information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Terns Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 4.75 per share. Given that Terns Pharmaceuticals has jensen alpha of (0.20), we advise you to double-check Terns Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.

Terns Pharmaceuticals Price Movement Analysis

Terns Pharmaceuticals Insider Trading Activities

Terns Pharmaceuticals Predictive Daily Indicators

Terns Pharmaceuticals Corporate Filings

Terns Pharmaceuticals Forecast Models

Terns Pharmaceuticals' time-series forecasting models are one of many Terns Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Terns Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Terns Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Terns shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Terns Pharmaceuticals. By using and applying Terns Stock analysis, traders can create a robust methodology for identifying Terns entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Terns analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Terns analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Terns Pharmaceuticals stock analysis indicators help investors evaluate how Terns Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Terns Pharmaceuticals shares will generate the highest return on investment. By understating and applying Terns Pharmaceuticals stock analysis, traders can identify Terns Pharmaceuticals position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

When running Terns Pharmaceuticals' price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Is Terns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.